- Price
- $9.73
- Day
- +1.46%
- Mkt Cap
- $90.96M
- 52W Range
- $6.01 – $17.44
- Volume
- 81.8K
- Beta
- 1.59
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
Read full article
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read full article
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference being held from September 14-16, 2026, in New York.Details o.
Read full article
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies
Read full article
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced completion of the last patient visit for the planned Phase 1 safety and efficacy analysis of prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN).
Read full article
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026. One individual was hired by Adicet in August 2026 and granted new hire non-qualified stock options to purchase 1,500 shares of Adicet's common stock with an exercis.
Read full article
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (m.
Read full article
Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.
Read full article